Arrowhead Pharmaceuticals, Inc. (ARWR)
Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease genes, mainly for metabolic and liver conditions. It last closed at $42.99 on Nov 17, down 2.76% on the day. ARWR reports earnings on Thu, Feb 4, 2027. The average 12-month price target from 6 analysts is $99.83 (+132.2% from the last close), with a high of $115.00 and a low of $74.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in ARWR, 33% of them bullish and 67% bearish. In the past 30 days there were 2 dark pool prints totaling $2.5M, the largest $1.5M.
Key Stats
Last 12 monthsNot reported for this period.
From ARWR's SEC filings, latest 10-K for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on ARWR in the past 90 days. The average target is $99.83, with a high of $115.00 and a low of $74.00, compared with the last close of $42.99.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | Citigroup | Target lowered | Buy | $108 → $105 |
| Nov 13 | RBC Capital | Reiterated | Buy | $100 |
| Nov 13 | Stifel | Target lowered | Buy | $98 → $96 |
| Oct 15 | UBS | Assumed coverage | Buy | $109 |
| Sep 24 | Goldman Sachs | Reinstated | Hold | $74 |
Technical Analysis
The stock is 28% below its 20 day and 43% below its 50 day average. It is 65% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the Pivot S1 at $41.86, and the nearest resistance the Pivot at $43.20.
| RSI (14) | 20.85 | Oversold below 30 | Oversold |
| MACD | -4.81 | Below its signal line | Bearish |
| Stochastic | 8.0 | Near the bottom of its range | Oversold |
| ADX (14) | 39.2 | Trending down | |
| Williams %R | -95.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -144.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −27.8% | Change over 10 sessions | Bearish |
| ATR (14) | $3.07 | Typical daily range, 7.1% of price |
| RSI (14) | 27.53 | Oversold below 30 | Oversold |
| MACD | -5.78 | Below its signal line | Bearish |
| Stochastic | 5.2 | Near the bottom of its range | Oversold |
| ADX (14) | 33.0 | Trending down | |
| Williams %R | -98.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -150.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −48.1% | Change over 10 sessions | Bearish |
| ATR (14) | $7.50 | Typical daily range, 17.4% of price |
What happened before
See how ARWR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARWR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ARWR in the last 90 days.
Dark Pool
30DARWR Institutional Ownership
Full report →- ●241 buying vs 250 selling
- ▼Held by funds -1.6 pts
- ▼Funds holding -18
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 487 | 505 | −3.6% |
| In funds' top 10 | 9 | 9 | 0.0% |
| Held by funds | 83.2% | 84.8% | −1.6 pts |
| New / increased | 67 / 174 | 124 / 154 | −13.3% |
| Reduced / sold out | 170 / 80 | 156 / 58 | +16.8% |
| Put/call ratio | 0.24 | 0.35 | −29.6% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARWR is in one of them and how their past ARWR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARWR in an article yet. Here's the latest on the wider market.
ARWR Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Dan GoldmanD · NY | Sell | $1K – $15K | Jan 31, 2023 | Feb 24, 2023 | 24 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biopharmaceutical company based in Pasadena, California. It develops medicines that use RNA interference to switch off genes that drive disease, aiming at conditions that traditional drugs have struggled to treat. Its approved product, REDEMPLO, treats adults with familial chylomicronemia syndrome, a rare genetic disorder that raises triglyceride levels. The company's pipeline targets lipid and liver diseases, and it licenses its technology to other drugmakers.
- Headquarters
- Pasadena, CA
- Founded
- 1989
- Website
- arrowheadpharma.com ↗



